Merck & Co. Stock: The Trend Is Clear, the Value Is Not
MRKMerck & Co., Inc.
DCF focus with Graham-Dodd
Gross margin of 75.9% (above 60%) → DCF as the primary model. Animal Health is too small for a sum-of-the-parts. Result: DCF $56 / 109 / 175, Graham-Dodd $78–99 – only the bull case is above the share price.
WACC explained → · DCF valuation explained → · CAPM / cost of equity explained → · Margin of safety explained →
Ahead of Q3 on Oct 29: What Matters
The analysis is dated Oct 23 (data through the Oct 22 close: $147.24). On Friday the stock closed at $145.27 (−1.3%) – right in the support zone formed by the SMA50 and the 23.6% Fibonacci level. Four points will drive the reaction to the numbers:
- Expectations. Consensus EPS of $2.09 on revenue of $17.35bn (Q2: $16.61bn). After the first half, 49% of the raised revenue guide ($66.3–67.3bn) is done – Merck is on track.
- Distorted earnings guide. EPS guidance was cut from $5.04–5.16 to $2.66–2.76 – entirely because of the Cidara ($3.62 per share) and Terns ($2.31 per share) acquisitions, which are expensed immediately as R&D. Operationally, this is not an earnings decline.
- Keytruda transition. Keytruda/Qlex brings in $8.4bn a quarter, roughly half of group revenue. What matters is how fast subcutaneous Qlex (Q2: $463m) grows – it is meant to protect revenue beyond the 2028 patent expiry. Winrevair (+75% to $588m) is the second growth driver.
- Politics. Around the US election on Nov 3, the drug-pricing debate remains the biggest sector risk.
Verdict: With the price in the 98th percentile of its own 5-year range, there is little room for disappointment. A close below $137 would confirm the correction scenario.
Fundamentals vs. Technicals
Fundamentals: stable, but deliberately distorted
Q2 revenue +5% ($16.61bn), guidance raised. The reported operating margin (−2.6%) is distorted by acquisition charges; adjusted it is stable around 35%. TTM FCF of about $15.2bn, dividend +4.9%, buybacks of $5.08bn (2025). The structural issue: roughly half of revenue depends on Keytruda, with the patent expiring in 2028.
Technicals: uptrend near the high
Price above the SMA50 and SMA200 (golden cross Oct 21, 2025), +73% in twelve months, 6.9% below the $156 all-time high and in the 98th percentile of the 5-year range. First signs of fatigue: the weekly MACD histogram is turning negative. The long-term death cross (SMA100/200, Mar 20, 2026) is lagging – the price is about 40% above the 200-week line.
Valuation: All Models at a Glance
| Model | Bear | Base | Bull | Base vs. price |
|---|---|---|---|---|
| DCF (FCF, WACC 7.2%) | $56 | $109 | $175 | −25.0% |
| Graham-Dodd (GAAP EPS $7.28 / fwd EPS $9.26) | $78 | $99 | – | −31.9% |
WACC: risk-free rate 4.96%, beta 0.60 (measured 0.22 – raised for realistic cost of capital), equity risk premium 4.46% → cost of equity 7.64%, WACC 7.20%. Base: TTM revenue of $66.6bn, FCF margin 20% → 20 / 24 / 27%; the bear case assumes revenue declines from the Keytruda patent expiry. Multiples cross-check: forward P/E of 15.6x vs. a peer median of 15.3x (Novartis, AstraZeneca) and 29.4x for the industry – not expensive on earnings.
Key Chart Levels
Support: SMA50 ($146.07) and the 23.6% Fibonacci level ($144.32). Invalidation: the 38.2% Fibonacci level, which is also the target of the weekly Elliott correction. Resistance: 20-day high and all-time high. Chart levels, not a trading recommendation.
Context Check (Macro)
With a beta of 0.22, Merck is a defensive name: the VIX rising to 19.8 (well above its 50-day average of 15.8) barely touches the stock, and defensive pharma names tend to benefit from rotation in nervous markets. The rate level is the headwind: the US 10-year yield sits at 4.96%, making dividend stocks relatively less attractive.
Next catalyst: Q3 results on Oct 29, 2026. The US election on Nov 3 follows, with the open question of where drug-price regulation goes next.
The Devil's Advocate
“The DCF punishes Merck for a year full of acquisitions – on earnings, the stock is no more expensive than Novartis or AstraZeneca.”
About $5.7bn of R&D charges for Cidara and Terns are one-offs. At a forward P/E of 15.6x, Merck trades in line with its closest peers and far below the industry (29.4x); EV/EBITDA (14.2x) is also slightly below the peer median.
Subcutaneous Qlex already generates $463m a quarter, Winrevair is growing 75%, and the acquisitions fill the pipeline. The very growth the DCF only assumes in the bull case is starting to show.
The current state (above the SMA200, neutral RSI) has historically been slightly above average for Merck (n = 9,932). The Elliott correction scenario is a counter-trend count with only a 35.8% probability.
Interactive DCF Calculator
| Item | Value | ||
|---|---|---|---|
Simplified model: TTM revenue of $66.6bn, growth fading linearly to 2% (terminal) over 10 years, FCF margin moving from 20% to the target within 5 years, 2.425bn shares. The net financial position is set so that the calculator reproduces the analysis base case ($109). Try it: only at ~8.2% initial growth (24% margin, 7.2% WACC) does the model reach the $145.27 share price.
| Market cap | ~$352bn |
| Forward P/E | 15.6x |
| Peer median fwd | 15.3x |
| EV/EBITDA | 14.2x |
| FCF TTM | ~$15.2bn |
| Dividend/quarter | $0.85 |
| Beta | 0.22 |
| 12M performance | +73.0% |
| 12M XLV (sector) | +26.3% |
| Q3 results | Oct 29, 2026 |
The current state (above the SMA200, neutral RSI) gave Merck only a small edge of +0.6 / +1.3 / +1.9 pp over the baseline after 5/10/20 days across n = 9,932 trading days. More telling: the weekly Elliott scenario of an A-B-C correction to $137 sits at 35.8%, below the trend baseline (49.2%) – fatigue yes, sell signal no.
- Full QualiStocks research report (as of Oct 22, 2026)
- Prices & indicators: yfinance, close Oct 22, 2026; headline price: close Oct 23, 2026
- Fundamentals: yfinance, Merck Q2/2026 report (8-K)
- Industry P/E, rates, VIX: Financial Modeling Prep
Position disclosure: at the time of publication, the author holds no position in MRK.
More analyses this week
AWS grows 39% and the operating margin hits a record 13.9%. Our SOTP base case rises from $217 to $224. After hours (≈ $227), the price is only about 1% above it.
Q3 revenue +26% and a clear earnings beat – yet −7% the next day. Capex of up to $145bn turns free cash flow negative; the price sits almost exactly on the DCF base case.
New analyses by email
Once a week: new analyses and updates on existing stocks. Free, unsubscribe anytime.